Dr Helen Parry MBChB, MSc, PhD, MRCP, FRCPath

Dr Helen Parry

Institute of Immunology and Immunotherapy
NIHR Clinical Lecturer

Contact details

Address
Institute of Immunology and Immunotherapy
Cancer Sciences Building
Mindelsohn Way
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Dr Helen Parry is a National Institute for Health Research (NIHR) academic clinical lecturer and works between the University of Birmingham and Queen Elizabeth Hospital, Birmingham. She has received funding from The Wellcome Trust (PhD fellowship), Academy of medical sciences (current), British Society of Haematology (current) and Queen Elizabeth Hospital charity (current education grant) funding.

Her current research areas include secondary immunodeficiency in haematological malignancies, and in particular Chronic Lymphocytic Leukaemia (CLL), for which she co-authored the British clinical guidelines. Her work involves studying patient immunity and the impact of novel therapies used to treat CLL and how we can improve current vaccination strategies to minimise infection risk. She is also interested in optimising the delivery of haematology services within a primary care setting and has an interest in medical education, being the co-founder of Blooducation. 

Qualifications

  • FRCPath 2018
  • PhD, University of Birmingham 2016
  • MRCP (UK) 2009
  • MBChB (Hons) University of Birmingham 2006
  • MSc (Distinction) in pathological studies, University of Birmingham 2005

Teaching

  • MBChB programme – Immunology and infection module; cancer module
  • Supervisor for intercalating BSc students

Research

Research themes:

  • Optimising vaccination strategies and minimising infection risk in patients with CLL
  • Investigating immunity in the setting of novel therapeutic agents

Publications

Recent publications

Article

Schuh, AH, Parry-Jones, N, Appleby, N, Bloor, A, Dearden, CE, Fegan, C, Follows, G, Fox, CP, Iyengar, S, Kennedy, B, McCarthy, H, Parry, HM, Patten, P, Pettitt, AR, Ringshausen, I, Walewska, R & Hillmen, P 2018, 'Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline', British Journal of Haematology, vol. 182, no. 3, pp. 344-359. https://doi.org/10.1111/bjh.15460

Zuo, J, Willcox, C, Mohammed, F, Davey, M, Hunter, S, Khan, K, Antoun , A, Katakia, P, Croudace, J, Inman, C, Parry, H, Briggs, D, Malladi, R, Willcox, B & Moss, P 2017, 'A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding', Science signaling, vol. 10, no. 481, eaai8904. https://doi.org/10.1126/scisignal.aai8904

Agathanggelou, A, Smith, E, Davies, N, Kwok, M, Zlatanou, A, Oldreive, C, Mao, J, Da Costa, D, Yadollahi, S, Perry, T, Kearns, P, Skowronska, A, Yates, E, Parry, H, Hillmen, P, Reverdy, C, Delansorne, R, Paneesha, S, Pratt, G, Moss, P, Taylor, M, Stewart, G & Stankovic, T 2017, 'USP7 inhibition alters homologous recombination repair and targets CLL cells independent of ATM/p53 functional status', Blood. https://doi.org/10.1182/blood-2016-12-758219, https://doi.org/10.1182/blood-2016-12-758219

Davies, N, Kwok, M, Gould, C, Oldreive, C, Mao, J, Parry, H, Smith, E, Agathanggelou, A, Pratt, G, Taylor, M, Moss, P, Griffiths, M & Stankovic, T 2017, 'Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts', OncoTarget, vol. 8, no. 27, pp. 44749-44760. https://doi.org/10.18632/oncotarget.17432

Parry, HM, Stevens, T, Oldreive, C, Zadran, B, Mcskeane, T, Rudzki, Z, Paneesha, S, Chadwick, C, Stankovic, T, Pratt, G, Zuo, J & Moss, P 2016, 'NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma', OncoTarget, vol. 7, pp. 68513-68526. https://doi.org/10.18632/oncotarget.12097

Parry, H, Damery, S, Hudson, C, Maurer, M, Cerhan, J, Pachnio, A, Begum, J, Slager, S, Fegan, C, Man, S, Pepper, C, Shanafelt, T, Pratt, G & Moss, P 2016, 'Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia', American Journal of Haematology, vol. 91, no. 8, pp. 776–781. https://doi.org/10.1002/ajh.24403

Pratt, G, Thomas, P, Marden, N, Alexander, D, Davis, Z, Hussey, D, Parry, H, Harding, S, Catovsky, D, Begley, J & Oscier, D 2016, 'Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival', Leukemia and Lymphoma, vol. 57, no. 10, pp. 2342-2350. https://doi.org/10.3109/10428194.2015.1137291

Kwok, M, Davies, N, Agathanggelou, A, Smith, E, Oldreive, C, Petermann, E, Stewart, G, Brown, J, Lau, A, Pratt, G, Parry, H, Taylor, M, Moss, P, Hillmen, P & Stankovic, T 2016, 'ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells', Blood, vol. 127, no. 5, pp. 582-595. https://doi.org/10.1182/blood-2015-05-644872

Parry, HM, Zuo, J, Frumento, G, Mirajkar, N, Inman, C, Edwards, E, Griffiths, M, Pratt, G & Moss, P 2016, 'Cytomegalovirus viral load within blood increases markedly in healthy people over the age of 70 years', Immunity & Ageing, vol. 13, 1. https://doi.org/10.1186/s12979-015-0056-6

Koczula, KM, Ludwig, C, Hayden, R, Cronin, L, Pratt, G, Parry, H, Tennant, D, Drayson, M, Bunce, CM, Khanim, FL & Günther, UL 2016, 'Metabolic plasticity in CLL: adaptation to the hypoxic niche', Leukemia, vol. 30, no. 1, pp. 65–73. https://doi.org/10.1038/leu.2015.187

Parry, HM, Birtwistle, J, Whitelegg, A, Hudson, C, McSkeane, T, Hazlewood, P, Mudongo, N, Pratt, G, Moss, P, Drayson, MT, Murray, J & Richter, AG 2015, 'Poor functional antibody responses are present in nearly all patients with chronic lymphocytic leukaemia, irrespective of total IgG concentration, and are associated with increased risk of infection', British Journal of Haematology, vol. 171, no. 5. https://doi.org/10.1111/bjh.13455

Oldreive, C, Skowronska, A, Davies, N, Parry, H, Agathanggelou, A, Krysov, S, Packham, G, Rudzki, Z, Cronin, L, Vrzalikova, K, Murray, P, Odintsova, E, Pratt, G, Taylor, M, Moss, P & Stankovic, T 2015, 'T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice', Disease Models and Mechanisms, vol. 8, pp. 1401-1412. https://doi.org/10.1242/dmm.021147

Parry, H, Damery, S, Mudondo, NP, Hazlewood, P, McSkeane, T, Aung, S, Murray, J, Pratt, G, Moss, P & Milligan, D 2015, 'Primary care management of early stage chronic lymphocytic leukaemia is safe and effective', QJM, vol. 108, no. 10, pp. 789-794. https://doi.org/10.1093/qjmed/hcv017

Letter

Ludwig, C, Williams, DS, Bartlett, DB, Essex, SJ, McNee, G, Allwood, JW, Jewell, E, Barkhuisen, A, Parry, H, Anandram, S, Nicolson, P, Gardener, C, Seymour, F, Basu, S, Dunn, WB, Moss, PAH, Pratt, G & Tennant, DA 2015, 'Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma', Blood Cancer Journal, vol. 5, e359. https://doi.org/10.1038/bcj.2015.85

View all publications in research portal